Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.79 |
| ▸ | CASP1 | P29466 | 1/20 | 0.79 |
| ▸ | CASP7 | P55210 | 1/20 | 0.79 |
| ▸ | CASP9 | P55211 | 1/20 | 0.79 |
| ▸ | EGFR | P00533 | 2/20 | 0.72 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6536461 | 0.91 | CASP3 (0.65) | CASP3CASP1CASP7CASP9EGFR | |
| SCHEMBL31395806 | 0.88 | CASP3 (1.00) | CASP3CASP1CASP7CASP9EGFR | |
| SCHEMBL2486952 | 0.88 | CASP3 (1.00) | CASP3CASP1CASP7CASP9EGFR | |
| SCHEMBL6535562 | 0.87 | CASP3 (1.00) | CASP3CASP1CASP7CASP9EGFR | |
| SCHEMBL31175908 | 0.87 | CASP3 (1.00) | CASP3CASP1CASP7CASP9EGFR | |
| SCHEMBL6535690 | 0.87 | CASP3 (1.00) | CASP3CASP1CASP7CASP9EGFR | |
| SCHEMBL30555459 | 0.84 | CASP3 (0.81) | CASP3CASP1CASP7CASP9EGFR | |
| SCHEMBL29059079 | 0.84 | CASP3 (0.81) | CASP3CASP1CASP7CASP9EGFR | |
| SCHEMBL5988598 | 0.83 | CASP3 (0.79) | CASP3CASP1CASP7CASP9 | |
| SCHEMBL6535582 | 0.81 | CASP3 (0.75) | CASP3CASP1CASP7CASP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6403792-B1 | INHIBIT PRODUCTION OF CASPASE 3 AND 7 IN MAMMALS | SMITHKLINE BEECHAM CORPORATION | 2002-06-11 | — | — | US | claimed |
| US-20240352012-A1 | PAN-CASPASE INHIBITORS | GEORGE MASON UNIVERSITY (US) | 2024-10-24 | — | — | US | disclosed |
| US-8987474-B2 | Inhibition of Shp2/PTPN11 protein tyrosine phosphatase by NSC-87877, NSC-117199 and their analogs | UNIVERSITY OF SOUTH FLORIDA (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987474-B2 | Inhibition of Shp2/PTPN11 protein tyrosine phosphatase by NSC-87877, NSC-117199 and their analogs | UNIVERSITY OF SOUTH FLORIDA (US) | 2015-03-24 | — | — | US | disclosed |
| US-20080176309-A1 | 8-hydroxy-7-(6-sulfonaphthalen-2-yl)diazenyl-quinoline-5-sulfonic acid (NSC-87877); Src homology-2 domains; Noonan syndrome, cancer | UNIVERSITY OF SOUTH FLORIDA (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080176309-A1 | 8-hydroxy-7-(6-sulfonaphthalen-2-yl)diazenyl-quinoline-5-sulfonic acid (NSC-87877); Src homology-2 domains; Noonan syndrome, cancer | UNIVERSITY OF SOUTH FLORIDA (US) | 2008-07-24 | — | — | US | disclosed |
| WO-2007117699-A2 | INHIBITION OF SHP2/PTPN11 PROTEIN TYROSINE PHOSPHATASE BY NSC-87877, NSC-117199 AND THEIR ANALOGS | UNIVERSITY OF SOUTH FLORIDA (US) | 2007-10-18 | — | — | WO | disclosed |
| WO-2004078731-A1 | QUINOLINE-CARBOXYLIC ACIDS AND THE DERIVATIVES THEREOF, A FOCUSED LIBRARY | 'CHEMICAL DIVERSITY RESEARCH INSTITUTE', LTD. (RU) | 2004-09-16 | — | — | WO | disclosed |
| EP-1242081-A4 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORP (US) | 2004-07-21 | — | — | EP | disclosed |
| EP-1001933-A4 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORP (US) | 2002-11-06 | — | — | EP | disclosed |
| EP-1242081-A1 | CASPASES AND APOPTOSIS | SmithKline Beecham Corporation (US) | 2002-09-25 | — | — | EP | disclosed |
| US-6403792-B1 | INHIBIT PRODUCTION OF CASPASE 3 AND 7 IN MAMMALS | SMITHKLINE BEECHAM CORPORATION | 2002-06-11 | — | — | US | disclosed |
| WO-2001022966-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-04-05 | — | — | WO | disclosed |
| EP-1001933-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999006367-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176309-A1 | 8-hydroxy-7-(6-sulfonaphthalen-2-yl)diazenyl-quinoline-5-sulfonic acid (NSC-87877); Src homology-2 domains; Noonan syndrome, cancer | PTPN7, PTPN1, PTPN2 | CASP3 4633/4885CASP1 4656/4885CASP7 799/4885 |
| US-20240352012-A1 | PAN-CASPASE INHIBITORS | CASP1, CASP2, CASP3 | CASP3 3/4885CASP1 1/4885CASP7 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.